|
23 Companies |
|
18 Products |
|
18 Products |
|
25 Mechanisms of Action |
|
0 Trials |
|
307 News |
|
| «1234567» |
- dobutamine / Generic mfg.
Trial completion, Trial primary completion date: Effects of Dobutamine on Microcirculation, Regional and Peripheral Perfusion in Septic Shock Patients (clinicaltrials.gov) - Jun 26, 2015
P=N/A, N=20, Completed, Sponsor: Pontificia Universidad Catolica de Chile
Recruiting --> Completed | Trial primary completion date: Aug 2012 --> Jan 2013
- Trial completion: Phase I STEBVax in Healthy Adults (clinicaltrials.gov) - Jun 15, 2015
P1, N=29, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | Trial primary completion date: Aug 2012 --> Jan 2013 Active, not recruiting --> Completed
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Trial primary completion date: Hyperglycemia and Effects of Daily 100 mg Versus 200 mg of Hydrocortisone Therapy in Patients With Septic Shock (clinicaltrials.gov) - Jun 11, 2015
P4, N=80, Recruiting, Sponsor: Srinakharinwirot University
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Jun 2016
- Trial completion: Effect of Different Strategies for Titrating a High MAP on Microcirculation (clinicaltrials.gov) - May 27, 2015
P4, N=20, Completed, Sponsor: Southeast University, China
Trial primary completion date: Dec 2015 --> Jun 2016 Recruiting --> Completed
- dexmedetomidine / Generic mfg.
Clinical: Dexmedetomidine on Microcirculation in Septic Shock (clinicaltrials.gov) - May 22, 2015
P4, N=26, Completed, Sponsor: Southeast University, China
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Oct 2015 --> Apr 2015
- Enrollment open, Trial initiation date, Trial primary completion date: Cerebral Oxygenation in Septic Patients Using Vasopressors - the Conscious Study (clinicaltrials.gov) - May 20, 2015
P=N/A, N=40, Recruiting, Sponsor: Karl-Andre Wian
Recruiting --> Completed | Trial primary completion date: Oct 2015 --> Apr 2015 Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Feb 2015 | Trial primary completion date: Sep 2015 --> Mar 2016
- | Enrollment closed, Trial primary completion date: VANCS II: Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients (clinicaltrials.gov) - May 20, 2015
P3, N=250, Active, not recruiting, Sponsor: Instituto do Cancer do Estado de S
Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Feb 2015 | Trial primary completion date: Sep 2015 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2013 --> Mar 2014
- Enrollment closed: Dynamic Changes of Tim-3 on Monocytes and Soluble Tim-3 in Patients With Sepsis (clinicaltrials.gov) - May 12, 2015
P=N/A, N=1, Active, not recruiting, Sponsor: Chinese PLA General Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2013 --> Mar 2014 Recruiting --> Active, not recruiting
- Trial completion, Trial primary completion date: Use of PiCCO System in Critically Ill Patients With Septic Shock and Acute Respiratory Distress Syndrome (clinicaltrials.gov) - May 4, 2015
P1/2, N=350, Completed, Sponsor: Jinhua Central Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Jan 2014 --> Jun 2014
- Biomarker, Trial completion, Enrollment change: Neutrophil Gelatinase Associated Lipocalin (NGAL) in Urine: Can This Prove to be a Biomarker for Acute Kidney Injury in Patients With Sepsis? (clinicaltrials.gov) - Apr 21, 2015
P=N/A, N=21, Completed, Sponsor: Sygehus Lillebaelt
Recruiting --> Completed | Trial primary completion date: Jan 2014 --> Jun 2014 Recruiting --> Completed | N=40 --> 21
- ||| hydrocortisone / Generic mfg.
Trial completion: Efficacy of Hydrocortisone in Treatment of Severe Sepsis/Septic Shock Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) (clinicaltrials.gov) - Apr 20, 2015
P=N/A, N=197, Completed, Sponsor: Mahidol University
Recruiting --> Completed | N=40 --> 21 Recruiting --> Completed
- ||| Enrollment change, Gram negative: GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults (clinicaltrials.gov) - Apr 15, 2015
P2, N=1415, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed N=1890 --> 1415
- |||| Trial completion, Gram negative: GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults (clinicaltrials.gov) - Apr 13, 2015
P2, N=1415, Completed, Sponsor: GlaxoSmithKline
N=1890 --> 1415 Terminated --> Completed
- Trial completion, Trial initiation date, Monotherapy, Head-to-Head: Efficacy and Safety of Monotherapy With Noradrenaline and Terlipressin in Patients of Cirrhosis With Septic Shock Admitted to Intensive Care Unit (clinicaltrials.gov) - Mar 31, 2015
P=N/A, N=84, Completed, Sponsor: Institute of Liver and Biliary Sciences, India
Terminated --> Completed Recruiting --> Completed | Initiation date: Apr 2013 --> Oct 2012
- ||| Trial completion: Procalcitonin Monitoring Sepsis Study (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=858, Completed, Sponsor: Brahms AG
Recruiting --> Completed | Initiation date: Apr 2013 --> Oct 2012 Recruiting --> Completed
- Enrollment open: SEPP1B: Correlation Between PTP1B Expression and Organ Failure During Sepsis (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=54, Recruiting, Sponsor: University Hospital, Rouen
Recruiting --> Completed Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Enrollment change, Trial withdrawal, Trial primary completion date: Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock (clinicaltrials.gov) - Feb 9, 2015
P=N/A, N=0, Withdrawn, Sponsor: Beth Israel Deaconess Medical Center
Not yet recruiting --> Recruiting N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jan 2011 --> Jan 2015
- ||| Trial completion: Venous Lactate in Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients in Emergency Department (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=392, Completed, Sponsor: Chulalongkorn University
N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jan 2011 --> Jan 2015 Recruiting --> Completed
- Enrollment change, Trial termination, Trial primary completion date: DOVSS: Discontinuation Order of Vasopressors in Septic Shock (clinicaltrials.gov) - Jan 30, 2015
P=N/A, N=78, Terminated, Sponsor: Samsung Medical Center
Recruiting --> Completed N=134 --> 78 | Recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Dec 2013; Futility by interim analysis
- ||| Clinical: Epidemiology, Acute Management, and Outcomes of Patients With Sepsis Presenting to a Referral Hospital in Western Kenya (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=440, Not yet recruiting, Sponsor: Duke University
- Trial completion, Trial primary completion date: Bio-clinical Evolutive Dynamic in Patients Suffering From Communitary Septic Shock (Biosepsis) (clinicaltrials.gov) - Jan 20, 2015
P=N/A, N=64, Completed, Sponsor: University Hospital, Grenoble
N=134 --> 78 | Recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Dec 2013; Futility by interim analysis Recruiting --> Completed | Trial primary completion date: Jun 2013 --> Oct 2012
- Trial completion, Enrollment change: SNA&Sepsis: Autonomic Nervous System Alteration Induce by Sepsis: Assessment and Prognosis Impact (clinicaltrials.gov) - Jan 20, 2015
P4, N=13, Completed, Sponsor: University Hospital, Grenoble
Recruiting --> Completed | Trial primary completion date: Jun 2013 --> Oct 2012 Recruiting --> Completed | N=30 --> 13
- New P1 trial: rTSST-1 Variant Vaccine Phase 1 (clinicaltrials.gov) - Jan 17, 2015
P1, N=46, Recruiting, Sponsor: Biomedizinische Forschungs gmbH
- Trial primary completion date: EARTH-ICU: Early Physical Therapy in Patients With Sepsis (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=36, Recruiting, Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Recruiting --> Completed | N=30 --> 13 Trial primary completion date: Dec 2014 --> Jul 2015
- Clinical: ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=32, Not yet recruiting, Sponsor: Alteco Medical AB
- || New P3 trial: Balanced Salt Solution VS. Normal Saline Solution in Septic Shock (clinicaltrials.gov) - Jan 13, 2015
P3, N=60, Active, not recruiting, Sponsor: Ramathibodi Hospital
- Enrollment open: Adsorbtion of Cytokines Early in Septic Shock: the ACESS Study (clinicaltrials.gov) - Dec 13, 2014
P=N/A, N=20, Recruiting, Sponsor: Domonkos Trásy
Trial primary completion date: Dec 2014 --> Jul 2015 Active, not recruiting --> Recruiting
- || Trial primary completion date: Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=361, Recruiting, Sponsor: University of British Columbia
Active, not recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- Enrollment change, Trial termination: Investigate the Activity of Endotoxin in Severe Sepsis (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=2, Terminated, Sponsor: National Taiwan University Hospital
Trial primary completion date: Dec 2014 --> Dec 2015 N=60 --> 2 | Recruiting --> Terminated; The quality of Limulus Amebocyte Lysate (LAL) test was poor.
- Enrollment closed: Phase I STEBVax in Healthy Adults (clinicaltrials.gov) - Dec 6, 2014
P1, N=29, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=60 --> 2 | Recruiting --> Terminated; The quality of Limulus Amebocyte Lysate (LAL) test was poor. Recruiting --> Active, not recruiting
- Trial termination: Utility of High-Fidelity Simulation In the Education and Assessment of Residents in the Recognition and Management of the Sepsis Syndrome (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=40, Terminated, Sponsor: New York University School of Medicine
Recruiting --> Active, not recruiting Not yet recruiting --> Terminated; Key Personnel left institution
- Clinical: OFTaPLR: Optimization of Fluid Therapy in Sepsis by a Passive Leg Raising Test (clinicaltrials.gov) - Nov 28, 2014
P=N/A, N=120, Recruiting, Sponsor: Karolinska Institutet
- Trial termination, Trial primary completion date: Hyper2S: Hyperoxia and Hypertonic Saline in Septic Shock (clinicaltrials.gov) - Nov 20, 2014
P=N/A, N=441, Terminated, Sponsor: University Hospital, Angers
Not yet recruiting --> Terminated; Key Personnel left institution Active, not recruiting --> Terminated | Trial primary completion date: Jun 2014 --> Sep 2014
- Biomarker, Trial primary completion date: Neutrophil Gelatinase Associated Lipocalin (NGAL) in Urine: Can This Prove to be a Biomarker for Acute Kidney Injury in Patients With Sepsis? (clinicaltrials.gov) - Nov 18, 2014
P=N/A, N=40, Recruiting, Sponsor: Sygehus Lillebaelt
Active, not recruiting --> Terminated | Trial primary completion date: Jun 2014 --> Sep 2014 Trial primary completion date: Jul 2014 --> Jun 2015
- dexmedetomidine / Generic mfg.
Clinical: Dexmedetomidine on Microcirculation in Septic Shock (clinicaltrials.gov) - Oct 30, 2014
P4, N=30, Recruiting, Sponsor: Southeast University, China
Trial primary completion date: Jul 2014 --> Jun 2015 Not yet recruiting --> Recruiting
- dexmedetomidine / Generic mfg.
Clinical: Dexmedetomidine on Microcirculation in Septic Shock (clinicaltrials.gov) - Oct 22, 2014
P4, N=30, Not yet recruiting, Sponsor: Southeast University, China
- | Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
New P4 trial: Hyperglycemia and Effects of Daily 100 mg Versus 200 mg of Hydrocortisone Therapy in Patients With Septic Shock (clinicaltrials.gov) - Oct 17, 2014
P4, N=80, Recruiting, Sponsor: Srinakharinwirot University
- || hydrocortisone / Generic mfg.
New P3 trial: Stress Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock (clinicaltrials.gov) - Oct 17, 2014
P3, N=84, Completed, Sponsor: Nanjing PLA General Hospital
- | Trial completion: TRISS: Transfusion-requirements in Septic Shock Trial (clinicaltrials.gov) - Oct 4, 2014
P3, N=1005, Completed, Sponsor: Scandinavian Critical Care Trials Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Gohibic (vilobelimab) / Staidson Biopharma, InflaRx
New P2 trial: SCIENS: Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction (clinicaltrials.gov) - Sep 28, 2014
P2, N=72, Recruiting, Sponsor: InflaRx GmbH
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Integrilin (eptifibatide) / Takeda
Enrollment open: CO-ILEPSS: Co-administration of Iloprost and Eptifibatide in Septic Shock Patients (clinicaltrials.gov) - Sep 28, 2014
P2, N=18, Recruiting, Sponsor: Sisse R. Ostrowski, MD PhD DMSc
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion, Enrollment change: Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=122, Completed, Sponsor: National University Hospital, Singapore
Not yet recruiting --> Recruiting Recruiting --> Completed | N=160 --> 122
- Clinical: Cerebral Oxygenation in Septic Patients Using Vasopressors - the Conscious Study (clinicaltrials.gov) - Sep 11, 2014
P=N/A, N=40, Not yet recruiting, Sponsor: Karl-Andre Wian
- Enrollment open, Trial initiation date, Trial primary completion date: CLASSIC: Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care (clinicaltrials.gov) - Sep 8, 2014
P4, N=150, Recruiting, Sponsor: Anders Perner
Recruiting --> Completed | N=160 --> 122 Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Sep 2014 | Trial primary completion date: Mar 2015 --> Aug 2015
- Trial completion: International Multicentre Prevalence Study on Sepsis (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=1000, Completed, Sponsor: European Society of Intensive Care Medicine
Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Sep 2014 | Trial primary completion date: Mar 2015 --> Aug 2015 Recruiting --> Completed
- Neo-Synephrine (phenylephrine hydrochloride ophthalmic solution) / Paragon BioTeck, Bausch Health, Akorn
Enrollment open: Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients (clinicaltrials.gov) - Aug 15, 2014
P4, N=75, Recruiting, Sponsor: Vanderbilt University
Recruiting --> Completed Not yet recruiting --> Recruiting
- meropenem / Generic mfg.
New P4 trial: Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units (clinicaltrials.gov) - Aug 11, 2014
P4, N=9, Completed, Sponsor: Sutep Jaruratanasirikul
- | Neo-Synephrine (phenylephrine hydrochloride ophthalmic solution) / Paragon BioTeck, Bausch Health, Akorn
New P4 trial: Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients (clinicaltrials.gov) - Jul 30, 2014
P4, N=75, Not yet recruiting, Sponsor: Vanderbilt University
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Integrilin (eptifibatide) / Takeda
New P2 trial: CO-ILEPSS: Co-administration of Iloprost and Eptifibatide in Septic Shock Patients (clinicaltrials.gov) - Jul 30, 2014
P2, N=18, Not yet recruiting, Sponsor: Sisse R. Ostrowski, MD PhD DMSc
- midazolam hydrochloride / Generic mfg., dexmedetomidine / Generic mfg.
Clinical: The Effect of Dexmedetomidine on Microcirculation in Severe Sepsis (clinicaltrials.gov) - Jul 27, 2014
P4, N=60, Recruiting, Sponsor: National Taiwan University Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Jul 2014